Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (August 2020)
21 slides from Microbot Medical's investor presentation, Aug 17, 2020
Slide 1: Robotizing Endolumen Surgery
microbot medical ROBOTIZING ENDOLUMEN SURGERY NASDAQ:MBOT
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT microbot This document contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot. Forwa
Slide 3: Medical Robotics Market Is Rapidly Growing
MEDICAL ROBOTICS MARKET IS RAPIDLY GROWING microbot Minimally Invasive Surgery (MIS) is the fastest growing healthcare segment >$50B Becoming Smaller, Automated, and More Precise
Slide 4: Surgical Robotics Growth Opportunity
SURGICAL ROBOTICS GROWTH OPPORTUNITY microbot U.S. Market for Surgical Robotics © ~95% of Addressable Market Remains Available Microbot Medical is in the Right Market, at the Right Time with the Right Products!
Slide 5: Healthcare Landscape: Positioned for Post COVID-19
HEALTHCARE LANDSCAPE microbot POSITIONED FOR POST COVID-19 @ Telehealth has been a core focus of Microbot’s product development roadmap @LIBERTY and SCS are designed to be remote controlled and monitored medical Cardiovascular Today, April 2020 COVID-19: Robotics may help to reduce exposure to virus
Slide 6: Medical Robotics Remains in the Spotlight
MEDICAL ROBOTICS REMAINS IN THE SPOTLIGHT micropot : Medtronic Announces Acquisition of Digital Surgery to Accelerate Robot Medtronic Assisted Surgery Strategy. Globe Newswire, February 2020 INT UIT IVE Intuitive Surgical Acquires Orpheus Medical for Undisclosed Amount. Globe Newswire, February 2020
Slide 7: Evolution of Surgery
EVOLUTION OF SURGERY microbot Tomorrow Micro-robotics Today Robot Assisted Surgery 1990-2000 Minimally Invasive Surgery 1980-1990 Freehand Surgery
Slide 8: Multiple Opportunities — Endoluminal Surgery
MULTIPLE OPPORTUNITIES — ENDOLUMINAL SURGERY micromet
Slide 9: 2020 Key Milestones Achieved
2020 KEY MILESTONES ACHIEVED microbot Strengthened IP Portfolio: 38 Global Patents Issued/Allowed 19 Pending Patent Applications fbemicyy Unveiled First Ever Fully e Recruited Thought Leaders to Enhance Core Capabilities: Disposable Robotic System + Scientific Advisory Board: Dr. N Dr. Yaniv, Dr. Wa
Slide 10: LIBERTY
ibe microbot medical
Slide 11: Fully Disposable Robotic System
FULLY DISPOSABLE ROBOTIC SYSTEM microbot Operated Remotely
Slide 12: Animal Feasibility Study: Objectives
ANIMAL FEASIBILITY STUDY: OBJECTIVES microbot ®@ Test the System in Peripheral and Neuro Procedures ® Evaluate Safety Measures ® Confirm Usability of the System with Leading KOL’s libe microbot medical *The LIBERTY Robotic System is under its R&D phase, was not tested clinically and is not cleared f
Slide 13: Animal Feasibility Study: Met Primary Endpoints
ANIMAL FEASIBILITY STUDY: MET PRIMARY ENDPOINTS ® Peripheral and Neuro Procedures Successfully Achieved ®@ No Intraoperative Adverse Effects @® Performed Flawlessly During Animal Study libe microbot medical microbot medical
Slide 14: LIBERTY: Clinical and Regulatory Upcoming Milestones
LIBERTY: feral : CLINICAL AND REGULATORY UPCOMING MILESTONES micro LIBERTY: FDA 510(k) Submission 4Q22 LIBERTY: One & Done LIBERTY: Initiate Animal Vascular Studies a ret System Pre-Submission on-going 4Q21 LIBERTY: FDA 510(k) Clinical Trial 1Q22
Slide 15: Self-Cleaning Shunt (SCS): Ventriculoperitoneal Shunt Market Opportunity
SELF-CLEANING SHUNT (SCS): Crab t VENTRICULOPERITONEAL SHUNT MARKET OPPORTUNITY ™ICFoot
Slide 16: Self-Cleaning Shunt (SCS): Ventriculoperitoneal Shunt Market Opportunity
SELF-CLEANING SHUNT (SCS): Crab t VENTRICULOPERITONEAL SHUNT MARKET OPPORTUNITY ™ICFoot @ Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain. @ Over 1,000,000 people in t
Slide 17: SCS: Clinical and Regulatory Upcoming Milestones
SCs: feral t CLINICAL AND REGULATORY UPCOMING MILESTONES micro SCs: Wash U Animal Study Report 3Q20 Sscs: EFS Design Freeze Scs: 3021 Pre-Submission Scs: IDE Submission for FIH 4Q22 Supplement 3Q20
Slide 18: Robust IP Platform
ROBUST IP PLATFORM microbot 38 Patents ee Z e issued/ allowed i Applications pending worldwide Selt- Disposable Restenosis eat ee ow Robotic eit Endoluminal Acasa imaging anes Soncentric ete ‘Shut System Guidewire System
Slide 19: Proven Founders
PROVEN FOUNDERS micropot medical Prof. Moshe Shoham Member of the Scientific Advisory Board Prof. Moshe Shoham is a worldwide acclaimed authority in the field of robotics, conducting research in the robotic field for over the past 25 years, with a special focus on kinematics and dynamics of robots,
Slide 20: Proven Leadership Team
PROVEN LEADERSHIP TEAM Simon Sharon Chief Technology Officer Mr. Simon Sharon brings 23 years of R&D and general management in the medical devices space. Prior to Microbot Medical Mr. Sharon managed the R&D at Icecure Medical; an early stage, public medical device company. Mr. Sharon was the General
Slide 21: Summary
SUMMARY microbot Developing micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs Significant IP creates barrier to entry Strong cash position to achieve meaningful milestones
Microbot Medical — Investor Presentation (August 2020) on 6ix